Hikma Pharmaceuticals (OTCMKTS:HKMPF) Hits New 1-Year Low – Here’s What Happened

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)’s share price reached a new 52-week low on Thursday . The stock traded as low as $19.34 and last traded at $19.34, with a volume of 310 shares changing hands. The stock had previously closed at $21.76.

Hikma Pharmaceuticals News Roundup

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: U.S. legal development could protect Hikma’s Vascepa generic position — the U.S. Solicitor General urged dismissal of Amarin’s challenge around “skinny labels,” a ruling that would be supportive of Hikma’s position in the Vascepa patent dispute. As SCOTUS takes on ‘skinny label’ review, top US lawyer sides with generics maker
• Positive Sentiment: Share-buyback announced and underway — Hikma launched a $250m repurchase program and made an initial ~£1.2m purchase, a clear capital-return signal that can support the share price longer term. Hikma launches $250m buyback with first £1.2m share purchase
• Positive Sentiment: Underlying sales momentum — 2025 core revenue rose ~6% with injectables performing strongly, supporting the company’s fundamentals despite near-term headwinds. UK’s Hikma posts higher annual revenue on strong injectables segment
• Neutral Sentiment: Company recap: revenue growth + buyback + leadership overhaul — the firm packaged these items together as its strategic response to the outlook; impact depends on execution and investor confidence. Hikma posts revenue growth, launches $250m buyback and overhauls leadership
• Negative Sentiment: Weaker 2026 guidance spooked investors — management issued softer guidance for 2026, triggering a sharp sell-off as the market focused on near-term growth risks. Hikma Pharma tumbles on softer guidance as buyback fails to soften pill
• Negative Sentiment: Leadership shuffle seen as reaction to weak outlook — executive chair to serve as full-time CEO and other senior moves have been framed as a response to performance, which increased investor uncertainty. Hikma Pharmaceuticals rejigs top team as shares slide on weak outlook
• Negative Sentiment: Market reaction: shares hit multi-year lows — commentary and headlines calling out a three‑year low amplified selling pressure despite the buyback. Hikma Pharma shares plunge to over three-year low on weak outlook

Wall Street Analyst Weigh In

Separately, Barclays lowered shares of Hikma Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 6th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Hikma Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.24 and a quick ratio of 0.72. The stock’s 50-day simple moving average is $20.92 and its two-hundred day simple moving average is $22.01.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.